Phase 2a Clinical Study to evaluate efficacy and safety of JTE-451 ointment in patients with plaque psoriasis.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210232

Enrollment

Registered

2021-08-06

Start date

2021-08-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis

Interventions

An appropriate amount of JTE-451 or placebo ointment will be applied to the areas affected by plaque psoriasis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Japanese subjects who have clinical diagnosis of chronic plaque psoriasis for at least 6 months and whose disease condition is stable, at informed consent 2. Subjects with a PASI score >=5.0 3. Subjects with a PGA score of 2, 3 or 4 4. Subjects with BSA affected >=3% and <=20% (except for the hairy scalp)

Exclusion criteria

Exclusion criteria: 1. Subjects with psoriasis other than plaque psoriasis 2. Subjects who have shown no efficacy by treatment with specific biologics 3. Subjects with dermatologic or inflammatory condition that would affect the study assessments determined by the investigator 4. Subjects with acute active bacterial, fungal or viral skin infection

Design outcomes

Primary

Measure	Time frame
Proportion of subjects with >=75% improvement in PASI score from Baseline	—

Contacts

Public Contactclinical trials information

Shionogi & Co.,Ltd.

clinicaltrials-info@shionogi.co.jp+81-3-6635-3505

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026